Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9781838 | 0.86 | L3MBTL1 (0.65) | L3MBTL1ALOX5LTA4H | |
| SCHEMBL19784439 | 0.82 | L3MBTL1 (0.69) | L3MBTL1ALOX5LTA4HTDP1 | |
| SCHEMBL6629239 | 0.78 | L3MBTL1 (0.73) | L3MBTL1 | |
| SCHEMBL8899583 | 0.77 | L3MBTL1 (0.76) | L3MBTL1 | |
| SCHEMBL13823926 | 0.77 | L3MBTL1 (0.72) | L3MBTL1 | |
| SCHEMBL9781776 | 0.76 | L3MBTL1 (0.78) | L3MBTL1 | |
| SCHEMBL9434959 | 0.76 | L3MBTL1 (0.78) | L3MBTL1 | |
| SCHEMBL9434778 | 0.76 | L3MBTL1 (0.78) | L3MBTL1 | |
| SCHEMBL30945299 | 0.76 | L3MBTL1 (0.69) | L3MBTL1 | |
| SCHEMBL8300753 | 0.76 | L3MBTL1 (0.69) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492523-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-05 | — | — | EP | disclosed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | RNASE1, GUSB, DPEP1 | L3MBTL1 2996/4885ALOX5 790/4885LTA4H 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.